Documentation scienceplus.abes.fr version Bêta

À propos de : Mibefradil — a drug which may enhance the propensity for the development of abnormal QT prolongation        

AttributsValeurs
type
Is Part Of
Subject
Title
  • Mibefradil — a drug which may enhance the propensity for the development of abnormal QT prolongation
has manifestation of work
related by
Author
Abstract
  • Mibefradil is a moral calcium antagonist that is selective for the T-type voltage-operated calcium channel. It has been shown to be effective in hypertension and in stable angina. Shortly following its introduction, mibefradil was withdrawn from the market because of potentially harmful interactions with other drugs. Of special interest is the possible interaction of mibefradil with drugs which prolong the QT interval (e.g. amiodarone, quinidine, sotalol, erythromycin, desimipramine and thioridazine). This short review summarizes the effects of mibefradil on cardiac repolarization and possible implications for drug interactions with QT prolonging agents.
article type
is part of this journal



Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata